Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Early Phase 1
1(50.0%)
2Total
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07439172Phase 2Not Yet Recruiting

Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.

Role: collaborator

NCT03593993Terminated

A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas

Role: collaborator

NCT00874861Early Phase 1Completed

HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas

Role: collaborator

All 3 trials loaded